InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,634.58
(
0.03%
)
US TECH 100
18,946.40
(
0.04%
)
Dow Jones
41,606.18
(
-0.04%
)
Brent Oil
72.21
(
-1.52%
)
Bitcoin
60,035.39
(
-0.44%
)
Post# of 253142
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120456
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 221443

Thursday, 03/21/2019 6:22:48 PM

Thursday, March 21, 2019 6:22:48 PM

Post# of 253142
(ENTA)—JNJ formally abandons RSV program:

https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm

On March 21, 2019, Johnson & Johnson…determined that it will record an intangible asset impairment charge related to an in-process research and development asset, AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV), with a carrying value of approximately $900 million acquired in the acquisition of Alios Biopharma Inc. in 2014.

Additional information became available which led the Company to the decision to abandon the development of AL-8176.

Bullish for ENTA, of course. (h/t @bio_clouseau.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up